In a recent decision, McAirlaids, Inc. v. Kimberly-Clark
Corporation, F.3d (4th Cir. 2014), the Fourth
Circuit reversed and remanded a summary judgment order after
finding there were triable issues regarding whether a dot pattern
for absorbent pads is functional. This decision reflects the
ongoing struggle with how to apply the Supreme Court's holding
in Traffix Devices v. Marketing Displays and distinguish
between functional and non-functional trade dress when a utility
patent is involved.
McAirlaids made absorbent pads for medical or hygienic use that
contain the pixel-embossed dot pattern shown below:
McAirlaids owned a federal registration for the above pattern
based on acquired distinctiveness and filed suit in the Western
District of Virginia against Kimberly-Clark for trade-dress
infringement and unfair competition after Kimberly-Clark began
using a similar dot pattern on its GoodNites bed mats.
Even though McAirlaids owned a utility patent for the absorbent
pads, it asserted that its dot pattern was ornamental and did not
serve a utilitarian function. In Traffix, the Supreme
Court held that the presence of a utility patent is strong evidence
of functionality. Accordingly, Kimberly-Clark argued that
McAirlaids' utility patent was strong evidence that the dot
pattern was functional and thus not protectable as trade dress. The
district court agreed and granted summary judgment to
Kimberly-Clark. McAirlaids appealed.
On appeal, the Fourth Circuit distinguished this case from
Traffix, finding that while McAirlaids's utility
patents covered the manufacturing process and materials of the
absorbent pads, a question of fact remained as to whether the
patents pertained to the dot pattern. Further, the Fourth Circuit
held that the existence of a utility patent is only one of several
factors that the district court should have considered in
evaluating the functionality of the dot pattern. In that regard,
the district court failed to properly weigh McAirlaids' trade
dress registration, which is prima facie evidence that the trade
dress is non-functional. Also, McAirlaids had presented evidence of
alternative "functionally equivalent" designs to show
that no matter which dot pattern was used, the functionality of the
pads was the same, thus making its specific dot pattern
non-functional trade dress.
In light of these factual disputes regarding functionality, the
Fourth Circuit reversed the lower court's summary judgment
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
19 Jan 2017, Webinar, Washington, DC, United States
While the digital health industry promises a revolution in personalized healthcare by bringing together innovative software for healthcare data and cutting-edge life sciences advances, developing a meaningful patent portfolio around those innovations remains a challenge. Recent developments in the courts and at the USPTO have increased the difficulty of protecting those innovations, particularly where the underlying software or technology may build on abstract ideas or laws of nature.
24 Jan 2017, Speaking Engagement, Washington, DC, United States
The first webinar, gMaking the Biosimilar Business CaseExploring the Interface Between Economics and Patent Lawh will explore both the economic market factors of the biosimilar world and patent strategies, and how they impact target selection for biologics and biosimilars.
The second program, gDelivering the GoodsBiosimilar Development with an Eye Toward FDA Approvalh expands upon issues impacting biologics and biosimilar development. The final webinar, gLitigation Strategies in View of Recent Case Lawh explores strategies for the complicated multi-stage litigation process, the interface between district court and PTAB proceedings, and issues surrounding commercial launch.
24 Jan 2017, Webinar, Washington, DC, United States
This first webcast of our series will explore both the economic market factors of the biosimilar world and patent strategies, and how they impact target selection for biologics and biosimilars. In contrast to the development of generic small molecules, it has been reported that it takes seven to eight years to develop a biosimilar at a cost of between $100 million and $250 million.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
In June 2016, the NHL announced that Las Vegas would be awarded an NHL franchise team, the first major professional sports team in the city and the first new expansion team for the NHL in over fifteen years.
On December 6, 2016, the parties to the complex and soon-to-be departed world of patent interferences orally argued their positions on motions in what has been described as the "biotech trial of the century"...
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think youve read our Disclaimer).